SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:kth-303538"
 

Search: onr:"swepub:oai:DiVA.org:kth-303538" > Development of humo...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Högelin, Klara AsplundKarolinska Institutet (author)

Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier BV,2021
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:kth-303538
  • https://urn.kb.se/resolve?urn=urn:nbn:se:kth:diva-303538URI
  • https://doi.org/10.1016/j.isci.2021.103078DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:147751254URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • QC 20211103
  • B cell depleting therapies (BCDTs) are widely used as immunomodulating agents for autoimmune diseases such as multiple sclerosis. Their possible impact on development of immunity to severe acute respiratory syndrome virus-2 (SARS-CoV-2) has raised concerns with the coronavirus disease 2019 (COVID-19) pandemic. We here evaluated the frequency of COVID-19-like symptoms and determined immunological responses in participants of an observational trial comprising several multiple sclerosis disease modulatory drugs (COMBAT-MS; NCT03193866) and in eleven patients after vaccination, with a focus on BCDT. Almost all seropositive and 17.9% of seronegative patients on BCDT, enriched for a history of COVID-19-like symptoms, developed anti-SARS-CoV-2 T cell memory, and T cells displayed functional similarity to controls producing IFN-gamma and TNF. Following vaccination, vaccine-specific humoral memory was impaired, while all patients developed a specific T cell response. These results indicate that BCDTs do not abrogate SARS-CoV-2 cellular memory and provide a possible explanation as to why the majority of patients on BCDTs recover from COVID-19.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ruffin, NicolasKarolinska Institutet (author)
  • Pin, ElisaKTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab(Swepub:kth)u1pmjyje (author)
  • Månberg, Anna,1985-KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik(Swepub:kth)u1g5roxd (author)
  • Hober, Sophia,Professor,1965-KTH,Science for Life Laboratory, SciLifeLab,Proteinteknologi(Swepub:kth)u11qqzc1 (author)
  • Gafvelin, GuroKarolinska Inst, Ctr Mol Med L8 02, Dept Clin Neurosci, Therapeut Immune Design Unit, S-17176 Stockholm, Sweden. (author)
  • Grönlund, HansKarolinska Institutet (author)
  • Nilsson, PeterKTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik(Swepub:kth)u1ws88sk (author)
  • Khademi, MohsenKarolinska Institutet (author)
  • Olsson, TomasKarolinska Institutet (author)
  • Piehl, FredrikKarolinska Institutet (author)
  • Al Nimer, FaiezKarolinska Institutet (author)
  • Karolinska InstitutetAffinitets-proteomik (creator_code:org_t)

Related titles

  • In:iScience: Elsevier BV24:92589-0042

Internet link

Find in a library

  • iScience (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view